1
|
Berk BD, Bole R, Lundy SD, Vij SC. A review of the changing landscape of vasectomy trends in the United States in the post-dobbs era. Int J Impot Res 2025:10.1038/s41443-025-01053-2. [PMID: 40185908 DOI: 10.1038/s41443-025-01053-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Revised: 02/24/2025] [Accepted: 03/20/2025] [Indexed: 04/07/2025]
Abstract
The United States (U.S.) Supreme Court declared abortion unconstitutional in June 2022 in the Dobbs v. Women's Health Organization hearing. This decision sent shockwaves through the political and medical community. While the immediate impact on female reproductive rights was readily apparent, male counterparts also sought to assert their reproductive autonomy as evidenced by the rapid rise in vasectomy interest across the country. In the months following the decision, rates of vasectomy interest, as measured by Google Search Trends, and vasectomy procedure rates were noted to be increasing across the country. This review aims to summarize the current literature surrounding vasectomy trends following the Dobbs decision, with particular focus on the impact on vasectomy trends in various geographic regions and across different age groups and marital status. To date, five studies have been published exploring increasing public interest in vasectomy, as measured by internet search trends, five studies have been published exploring trends in vasectomy consultation post-Dobbs, including three primary single-center studies, and one study has been published regarding social media themes surrounding vasectomy in the U.S. These data highlight the impact of the decisions regarding female reproductive rights on the healthcare decisions by males in this country, placing vasectomists at the heart of the discussion.
Collapse
Affiliation(s)
- Brittany D Berk
- Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, US.
| | - Raevti Bole
- Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, US
| | - Scott D Lundy
- Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, US
| | - Sarah C Vij
- Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, US
| |
Collapse
|
2
|
Hervas I, Pellegrini L, Valls L, Gil Julia M, Navarro-Gomezlechon A, Rivera-Egea R, Mossetti L, Jabaloyas JMM, Garrido N. Effect of time since vasectomy on live birth rate of TESE‒ICSI egg donation cycles and male-related prognostic factors. Andrology 2025; 13:494-503. [PMID: 38997221 DOI: 10.1111/andr.13697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 06/19/2024] [Accepted: 07/03/2024] [Indexed: 07/14/2024]
Abstract
BACKGROUND Vasectomy is a widely used method of contraception. However, some men may have the desire to become biological fathers again after a period. OBJECTIVE To explore the effect of time since vasectomy and different male comorbidities on live birth rates from intracytoplasmic sperm injection cycles using donated oocytes by using testicular spermatozoa obtained by testicular sperm extraction. MATERIALS AND METHODS This was a retrospective study of 123 couples who underwent a testicular sperm extraction‒intracytoplasmic sperm injection cycle after vasectomy using donated oocytes. Subjects were divided into groups according to time since vasectomy and the male risk factor evaluated. The main outcomes measured were live birth rate per embryo transfer, per oocyte donation cycle, and per couple. We assessed the cumulative live birth rate according to the time since vasectomy and considered male comorbidities: body mass index, hypertension, diabetes mellitus, dyslipidemia, and smoking. RESULTS The overall live birth rate per couple was 59.3% (50.6-68.0). Considering the number of embryo transfer and oocyte donation cycle, the live birth rates were 34.1% (27.8-40.4) and 44.5% (36.9-52.1), respectively. The live birth rate according to time since vasectomy was not statistically different between groups. Consequently, the cumulative live birth rate was similar between the different interval times when considering one to eight embryo transfers (p = 0.74). No statistical differences in live birth rate and cumulative live birth rate were found between groups clustered according to male body mass index, smoking, hypertension, and dyslipidemia. However, diabetic male patients had a significantly lower rate of live birth rate per couple (22.2% [4.94-49.4]) than non-diabetic patients did (62.7% [53.7-71.8]) (p = 0.03), but not in their cumulative live birth rate. CONCLUSIONS The time since vasectomy seems to have no detrimental effects on the live birth rate and cumulative live birth rate in testicular sperm extraction‒intracytoplasmic sperm injection cycles with donated oocytes. Male diabetes negatively affects the overall live birth rate per couple, but not the cumulative live birth rate. These results could be useful for multidisciplinary patient-tailored counseling, regarding the chance of having a pregnancy and facilitating the decision-making process of the fertility specialists.
Collapse
Affiliation(s)
- Irene Hervas
- IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell, Valencia, Spain
| | | | - Lorena Valls
- Urology Unit, Hospital Clínico de Valencia, Av. de Blasco Ibáñez, Valencia, Spain
| | - Maria Gil Julia
- IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell, Valencia, Spain
| | - Ana Navarro-Gomezlechon
- IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell, Valencia, Spain
| | - Rocio Rivera-Egea
- Andrology Unit, IVIRMA Valencia, Plaza Policía Local, Valencia, Spain
| | - Laura Mossetti
- IVIRMA Global Research Alliance, IVIRMA Rome, Rome, Italy
| | - Jose Maria Martinez Jabaloyas
- Andrology Unit, IVIRMA Valencia, Plaza Policía Local, Valencia, Spain
- Department of Surgery, Valencia University, Av. Blasco Ibañez, Valencia, Spain
| | - Nicolas Garrido
- Urology Unit, Hospital Clínico de Valencia, Av. de Blasco Ibáñez, Valencia, Spain
| |
Collapse
|
3
|
Peacock J, James G, Atkinson M, Henderson J. Complications of vasectomy: results from a prospective audit of 105 393 procedures. BJU Int 2024; 134:789-795. [PMID: 38989696 DOI: 10.1111/bju.16463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/12/2024]
Abstract
OBJECTIVES To provide up-to-date complication rates for vasectomy in the UK using 15 years of data collected by the Association of Surgeons in Primary Care (ASPC). PATIENTS AND METHODS Data were collected between 2007 and March 2022. A patient questionnaire was completed on the day of surgery and at 4 months postoperatively. Rates of early and late failure, infection, hospital admission or re-admission, haematoma and post-vasectomy pain syndrome (PVPS) were recorded. There were no specific exclusion criteria. Complication rates were compared to those published by major urological organisations. Descriptive statistics were utilised, without formal statistical analysis. RESULTS Over the 15-year study period, data from 105 393 vasectomies were collected, performed by >150 surgeons. In 2022, 94.4% of surgeons used one test to prove sterility. In all, 65% of patients used a postal sperm test after vasectomy to confirm sterility. Early failure rates were available for 69 500 patients. Early failure occurred in 648 patients (0.93%). Of 99 124 patients, late failure occurred in 41 (0.04%). Of 102 549 vasectomies, postoperative infection was reported in 1250 patients (1.22%), haematoma in 1599 patients (1.56%), and PVPS was reported in 139 patients (0.14%). CONCLUSIONS Vasectomy remains a safe and reliable contraceptive method. The rates of complication were generally lower than those published by major urological organisations. This large, prospective audit provides accurate, contemporaneous complication rates that can form the basis for pre-vasectomy counselling.
Collapse
Affiliation(s)
- Julian Peacock
- Cheltenham General Hospital, Gloucestershire Hospitals NHS Trust, Cheltenham, UK
| | - Gareth James
- Association of Surgeons in Primary Care (ASPC), London, UK
| | | | - John Henderson
- Cheltenham General Hospital, Gloucestershire Hospitals NHS Trust, Cheltenham, UK
| |
Collapse
|
4
|
Khalafalla K, Ho CCK, Chung E, Atmoko W, Shah R, Agarwal A. Post-Vasectomy Semen Analysis: What's All the Fuss about? Diagnostics (Basel) 2024; 14:2275. [PMID: 39451597 PMCID: PMC11506271 DOI: 10.3390/diagnostics14202275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Revised: 10/02/2024] [Accepted: 10/04/2024] [Indexed: 10/26/2024] Open
Abstract
Vasectomy is a reliable male contraceptive method with a success rate exceeding 98%. Despite its efficacy, vasectomy is not foolproof, with potential early and late failures requiring careful postoperative monitoring via post-vasectomy semen analysis (PVSA). Published guidelines emphasize the necessity of conducting PVSA to ensure clinical sterility. Despite these clear guidelines, discrepancies in adherence and interpretation persist, with significant mismatches between guidelines and actual practice. Recent shifts in societal attitudes toward reproductive autonomy, spurred by significant political events and socioeconomic factors, have increased vasectomy rates, particularly among younger, childless men. This demographic change calls for enhanced PVSA compliance and clear communication about the non-immediate contraceptive effect of vasectomy. Home test kits have emerged as a convenient, though not always reliable, method for conducting PVSAs, which may require reevaluation in clinical practice. Given the variations across clinical guidelines and the challenges in achieving consistent PVSA outcomes, further research is needed to harmonize PVSA protocols across different health systems. PVSA is typically conducted between 8 and 16 weeks post-vasectomy, depending on the surgeon's preference. Success is confirmed when a fresh, uncentrifuged sample exhibits either azoospermia, rare non-motile sperm (RNMS), or fewer than 100,000 non-motile sperm per milliliter. This effort will ensure that both patients and practitioners can rely on vasectomy as a safe and effective form of contraception. Effective patient counseling and strategic follow-up are crucial when it comes to managing expectations and ensuring compliance with post-vasectomy protocols, thereby minimizing the risk of unintended pregnancies post-procedure.
Collapse
Affiliation(s)
- Kareim Khalafalla
- Department of Urology, Hamad Medical Corporation, Doha, Qatar;
- Department of Urology, College of Medicine, Qatar University, Doha, Qatar
- Global Andrology Forum, Moreland Hills, OH 44022, USA
| | - Christopher Chee Kong Ho
- Global Andrology Forum, Moreland Hills, OH 44022, USA
- Department of Surgery, School of Medicine, Taylor’s University, Subang Jaya, Selangor, Malaysia;
| | - Eric Chung
- Global Andrology Forum, Moreland Hills, OH 44022, USA
- Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia;
| | - Widi Atmoko
- Global Andrology Forum, Moreland Hills, OH 44022, USA
- Department of Urology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia;
| | - Rupin Shah
- Global Andrology Forum, Moreland Hills, OH 44022, USA
- Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India;
| | - Ashok Agarwal
- Global Andrology Forum, Moreland Hills, OH 44022, USA
- Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
5
|
Le KDR, Wang AJ, Haycock S, Shears MJ, Forbes M. A Scoping Review of the Clinical Utility of Laparoscopic Vasectomy. Cureus 2024; 16:e69022. [PMID: 39385913 PMCID: PMC11464007 DOI: 10.7759/cureus.69022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/09/2024] [Indexed: 10/12/2024] Open
Abstract
Vasectomy is a common procedure performed for family planning. Traditionally, this has been via a scrotal approach. In contrast, laparoscopic vasectomy is a documented but rarely described procedure that may minimise anaesthetic risk, surgical risk, and healthcare expenditure in patients undergoing elective laparoscopic procedures for concurrent pathology such as hernia repair. This scoping review evaluates the clinical utility of laparoscopic vasectomy. It was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Articles were identified with keywords related to laparoscopy and vasectomy. Six peer-reviewed, full-text articles published in English were included in this review. These studies encompass eight individual patient cases of laparoscopic vasectomy performed in the 1990s and early 2000s. All the cases included laparoscopy for concurrent pathology, the most common of which was inguinal hernia. There were no complications associated with laparoscopic vasectomy. For patients requiring laparoscopic surgery for alternate pathologies, synchronous laparoscopic vasectomy improves surgical efficiency by minimising anaesthetic time, operative time, and risk, in addition to lower associated healthcare costs. However, consideration is given to the limitations of this approach, and a note is made of the lack of evidence regarding safety and efficacy given the paucity of cases described in the literature.
Collapse
Affiliation(s)
- Khang Duy Ricky Le
- Geelong Clinical School, Deakin University School of Medicine, Geelong, AUS
- Department of General Surgical Specialties, The Royal Melbourne Hospital, Melbourne, AUS
- Department of Surgery, Northeast Health Wangaratta, Wangaratta, AUS
| | - Annie Jiao Wang
- Department of Surgery, Northeast Health Wangaratta, Wangaratta, AUS
- Department of General Surgical Specialties, The Royal Melbourne Hospital, Melbourne, AUS
| | - Shasha Haycock
- Department of Surgery, Northeast Health Wangaratta, Wangaratta, AUS
- Department of General Surgical Specialties, The Royal Melbourne Hospital, Melbourne, AUS
- Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, AUS
| | - Matthew J Shears
- Department of Surgery, Northeast Health Wangaratta, Wangaratta, AUS
| | - Mark Forbes
- Department of Urology, Northeast Health Wangaratta, Wangaratta, AUS
| |
Collapse
|
6
|
Kim J, So B, Heo Y, So H, Jo JK. Advances in Male Contraception: When Will the Novel Male Contraception be Available? World J Mens Health 2024; 42:487-501. [PMID: 38164023 PMCID: PMC11216971 DOI: 10.5534/wjmh.230118] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 07/18/2023] [Accepted: 07/26/2023] [Indexed: 01/03/2024] Open
Abstract
Many contraceptive methods have been developed over the years due to high demand. However, female contraceptive pills and devices do not work for all females due to health conditions and side effects. Also, the number of males who want to actively participate in family planning is gradually increasing. However, the only contraceptive options currently available to males are condoms and vasectomy. Therefore, many male contraceptive methods, including medication (hormonal and non-hormonal therapy) and mechanical methods, are under development. Reversibility, safety, persistence, degree of invasion, promptness, and the suppression of anti-sperm antibody formation are essential factors in the development of male contraceptive methods. In this paper, male contraceptive methods under development are reviewed according to those essential factors. Furthermore, the timeline for the availability of a new male contraception is discussed.
Collapse
Affiliation(s)
- Jongwon Kim
- Department of Medical and Digital Engineering, Hanyang University, Seoul, Korea
| | - Byeongchan So
- Department of Medical and Digital Engineering, Hanyang University, Seoul, Korea
| | - Yongki Heo
- Department of Medical and Digital Engineering, Hanyang University, Seoul, Korea
| | - Hongyun So
- Department of Medical and Digital Engineering, Hanyang University, Seoul, Korea
- Institute of Nano Science and Technology, Hanyang University, Seoul, Korea
- Department of Mechanical Engineering, Hanyang University, Seoul, Korea.
| | - Jung Ki Jo
- Department of Medical and Digital Engineering, Hanyang University, Seoul, Korea
- Department of Urology, College of Medicine, Hanyang University, Seoul, Korea.
| |
Collapse
|
7
|
Pierson BC, Banaag A, Janvrin ML, Koehlmoos TP. Vasectomy incidence in the military health system after the reversal of Roe v. Wade. Int J Impot Res 2024:10.1038/s41443-024-00905-7. [PMID: 38762601 DOI: 10.1038/s41443-024-00905-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 04/26/2024] [Accepted: 05/08/2024] [Indexed: 05/20/2024]
Abstract
Dobbs v. Jackson Women's Health Organization (Dobbs decision) has already had profound impact on reproductive health care in the United States. Some studies have reported increased incidence of vasectomy after the Dobbs decision. The Military Health System (MHS) provides a unique opportunity to evaluate this relationship in a universally insured, geographically representative population. We conducted a retrospective cross-sectional study of vasectomies among all male beneficiaries in the MHS, ages 18 to 64, from 2018 to 2022. Beneficiaries receiving a vasectomy were identified via billing data extraction from the MHS Data Repository (MDR). Descriptive statistics of demographic factors of all those receiving a vasectomy in the study period were evaluated. Crude and multivariate logistic regression models were used to evaluate for differences in demographic variables in those receiving a vasectomy pre-Dobb's decision as compared to after the Dobb's decision. The total number of men receiving a vasectomy each month over the study period was analyzed, as were the numbers in a state immediately implementing abortion access restrictions (Texas), and one without any restrictions on abortion access (Virginia). Our analysis found that men receiving a vasectomy post-Dobbs decision were more likely to be younger, unmarried, and of junior military rank than prior to the Dobbs decision. In the months following the Dobbs decision in 2022 (June-December), there was a 22.1% increase in vasectomy utilization as compared to the averages of those months in 2018-2021. Further, it was found that the relative increase in vasectomy after the Dobbs decision was greater in Texas (29.3%) compared to Virginia (10.6%). Our findings highlight the impact of the Dobbs decision on reproductive health care utilization outside of abortion.
Collapse
Affiliation(s)
- Benjamin C Pierson
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
| | - Amanda Banaag
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
| | - Miranda Lynn Janvrin
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
| | | |
Collapse
|
8
|
Drobner J, Fu MZ, Kaldany A, Velez-Leitner D. Historical Review of the Vasectomy: Antiquated Beliefs, Novel Techniques, and Contemporary Challenges. Urology 2023; 182:1-4. [PMID: 37783399 DOI: 10.1016/j.urology.2023.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/11/2023] [Accepted: 09/14/2023] [Indexed: 10/04/2023]
Affiliation(s)
- Jake Drobner
- Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
| | - Melinda Z Fu
- Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
| | - Alain Kaldany
- Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
| | | |
Collapse
|
9
|
Howard SA, Benhabbour SR. Non-Hormonal Contraception. J Clin Med 2023; 12:4791. [PMID: 37510905 PMCID: PMC10381146 DOI: 10.3390/jcm12144791] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 07/14/2023] [Accepted: 07/18/2023] [Indexed: 07/30/2023] Open
Abstract
While hormonal contraceptives are efficacious and available in several forms for women, perception of safety and concern over side effects are a deterrent for many. Existing non-hormonal contraceptives include permanent sterilization, copper intrauterine devices (IUDs), chemical/physical barriers such as spermicides and condoms, as well as traditional family planning methods including withdrawal and the rhythm method. Individuals who wish to retain their fertility in the future can achieve highest adherence and efficacy with long-acting, reversible contraceptives (LARCs), though there is only one, the copper IUD, that is non-hormonal. As rates of unintended pregnancies remain high with existing contraceptive options, it is becoming increasingly attractive to develop novel pregnancy prevention methods for both women and men. Non-hormonal contraceptives can target a variety of critical reproductive processes discussed here. This review focuses on identified non-hormonal contraceptive targets and subsequent drug candidates in development.
Collapse
Affiliation(s)
- Sarah Anne Howard
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Soumya Rahima Benhabbour
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| |
Collapse
|
10
|
White J, Rahman F, Petrella F, Rivero MJ, Deebel N, Arbeleaz MCS, Ledesma B, Kohn T, Ramasamy R. Telehealth Sterilization Consultation Does Not Impact Likelihood of Vasectomy: A Retrospective Institutional Analysis. Urology 2023; 176:79-81. [PMID: 37001823 DOI: 10.1016/j.urology.2023.03.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 03/08/2023] [Accepted: 03/18/2023] [Indexed: 03/31/2023]
Abstract
OBJECTIVE To evaluate if telehealth consultations would impact the likelihood of patients following through with vasectomies. METHODS We utilized electronic medical records from the past 5 years to retrospectively evaluate male patients undergoing a sterilization consult. Telehealth consultations have been offered since March 2020 due to the COVID-19 pandemic. Patients were stratified to in-office or telehealth consultation. We then utilized billing codes to determine if patients underwent a vasectomy. Percentages of patients who subsequently underwent vasectomy were compared using Chi-square analysis. Logistic regression was performed to identify factors associated with completing vasectomy. RESULTS There were a total of 369 patients who underwent a telehealth male sterilization consultation and 1664 patients who were seen in the office. We found that 66.9% of telehealth patients ultimately underwent a vasectomy (n.ß=.ß247) compared to 64.3% of patients who were seen via office assessment (n.ß=.ß1070) (X2 =.ß0.646, p.ß=.ß.724). Younger age was the only variable on univariate logistic regression that was associated with completing vasectomy (p.ß=.ß.002) via either an in-person or televisit, while body mass index, race, and ethnicity were not significant. CONCLUSION Only 2/3 of the men completing a vasectomy consult receive a subsequent vasectomy. Both in-office and telehealth consultations resulted in comparable rates of vasectomy. This is the first study to report on the likelihood of following through with a surgical procedure comparing in-office vs.ßtelehealth assessment in male sexual and reproductive medicine. As vasectomy consultations continue to rise, clinicians can be reassured by the effectiveness of telehealth consultations prior to vasectomy.
Collapse
Affiliation(s)
- Joshua White
- Desai Sethi Urology Institute, University of Miami, Miami, FL.
| | - Farah Rahman
- Desai Sethi Urology Institute, University of Miami, Miami, FL
| | - Francis Petrella
- Department of Urology, McGill University, Montreal, Quebec, Canada
| | | | - Nicholas Deebel
- Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC
| | | | - Braian Ledesma
- Desai Sethi Urology Institute, University of Miami, Miami, FL
| | - Taylor Kohn
- Department of Urology, John Hopkins University, Baltimore, MD
| | | |
Collapse
|
11
|
Hupertan V, Graziana JP, Schoentgen N, Boulenger De Hauteclocque A, Chaumel M, Ferretti L, Methorst C, Huyghe E. [Recommendations of the Committee of Andrology and Sexual Medicine of the AFU concerning the management of Vasectomy]. Prog Urol 2023; 33:223-236. [PMID: 36841700 DOI: 10.1016/j.purol.2022.12.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 12/22/2022] [Indexed: 02/27/2023]
Abstract
OBJECTIVES To answer the main clinical questions asked by practitioners and men consulting for a vasectomy request. METHOD The CPR method was used. The clinical questions were formulated according to the PICO methodology. A Pubmed literature search for the period 1984-2021 identified 508 references, of which 79 were selected and analyzed with the GRADE grid. RECOMMENDATIONS Vasectomy is a permanent, potentially reversible contraception. It is a safe procedure. A second vasectomy is necessary in only 1 % of cases. Surgical complications (hematoma, infection, pain, etc.) are rare. The frequency of prolonged scrotal pain after vasectomy is about 5 %, and less than 2 % describe a negative impact of this pain on their quality of life. Vasectomy does not have negative consequences on sexuality. The only contraindication to vasectomy is the minor patient. Patients at increased risk of remorse are single, divorced or separated men under the age of 30. Sperm storage may be particularly appropriate for them. Whatever the reason, the law allows the surgeon to refuse to perform the vasectomy. He must inform the patient of this at the first consultation. The choice of the type of anesthesia is left to the discretion of the surgeon and the patient. It must be decided during the preoperative consultation. Local anesthesia should be considered first. General anesthesia should be particularly considered in cases of anxiety or intense sensitivity of the patient to palpation of the vas deferens, difficulty palpating the vas deferens, or a history of scrotal surgery that would make the procedure more complex. Concerning the vasectomy technique, 2 points seem to improve the efficiency of the vasectomy: coagulation of the deferential mucosa and interposition of fascia. Leaving the proximal end of the vas deferens free seems to reduce the risk of post-vasectomy syndrome without increasing the risk of failure or complications. No-scalpel vasectomy is associated with a lower risk of postoperative complications than conventional vasectomy. Regarding follow-up, it is recommended to perform a spermogram at 3 months post-vasectomy and after 30 ejaculations. If there are still a few non-motile spermatozoa at 3 months, it is recommended that a check-up be performed at 6 months post-vasectomy. In case of motile spermatozoa or more than 100,000 immobile spermatozoa/mL at 6 months (defining failure), a new vasectomy should be considered. Contraception must be maintained until the effectiveness of the vasectomy is confirmed.
Collapse
Affiliation(s)
- V Hupertan
- Cabinet médical Paris Batignolles, Paris, France
| | - J P Graziana
- Clinique mutualiste de la porte de l'Orient, Lorient, France
| | - N Schoentgen
- Hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, Paris, France
| | | | - M Chaumel
- Service d'urologie, CHU de Tours, Tours, France
| | - L Ferretti
- Maison de santé pluridisciplinaire Bordeaux Bagatelle, Talence, France
| | - C Methorst
- Service d'urologie, CH des quatre villes, Saint-Cloud, France
| | - E Huyghe
- Département d'urologie, transplantation rénale et andrologie, CHU de Toulouse, site de Rangueil, Toulouse, France; Service de médecine de la reproduction, CHU de Toulouse, site de l'hôpital Paule-de-Viguier, 31059 Toulouse, France; UMR DEFE Inserm 1203, université de Toulouse 3, université de Montpellier, Toulouse, France.
| |
Collapse
|
12
|
Li Y, Zeng Q, Deng H, Xiang T, Qi W, Wu D. Ameliorating effect of gold nanoparticles decorated on biodegradable apple pectin modified magnetic nanoparticles on epididymo-orchitis inducing alterations in sperm quality and spermatogenic cells apoptosis. INORG CHEM COMMUN 2022. [DOI: 10.1016/j.inoche.2022.110089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
13
|
Ghomeshi A, Diaz P, Henry V, Ramasamy R, Masterson TA. The Interest in Permanent Contraception Peaked Following the Leaked Supreme Court Majority Opinion of Roe vs. Wade: A Cross-Sectional Google Trends Analysis. Cureus 2022; 14:e30582. [PMID: 36420253 PMCID: PMC9678014 DOI: 10.7759/cureus.30582] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 10/21/2022] [Indexed: 06/16/2023] Open
Abstract
Introduction With the leaked Supreme Court draft regarding Roe vs. Wade, substantial public reactions followed as the horizon of abortion laws within the United States of America have been changing. We sought to compare internet searches for vasectomy and tubal ligation seven days following the leaked draft on May 2, 2022. Methods We used public data provided by Google Trends to investigate the interest and geographic distribution of searches for the two forms of permanent contraception: Vasectomy and tubal ligation. We calculated the mean Search Volume Index (SVI) of these terms. Data analysis was performed with Microsoft Excel Version 16.60 (Redmond, USA), and comparisons between groups were performed using paired t-tests. Results The term 'vasectomy' saw a 121% increase (p=0.0063), and 'tubal ligation' had a 70% (p=0.029) increase compared to the week prior. 49/50 states had increased search inquiries for each term. However, the North and Southwestern regions of the U.S. had increased relative surge for vasectomy and the Midwest region for tubal ligation procedures, respectively. South Dakota and Idaho, with trigger laws that banned abortion immediately following the overturn of Roe vs. Wade, had the greatest surge in SVI for tubal ligation and vasectomy, respectively. Conclusion Our study indicates that with the potential overturn of Roe vs. Wade, there was a significantly increased interest in these two forms of permanent contraception. Future studies should investigate specific concerns and questions patients may have when it comes to the different options of contraception.
Collapse
Affiliation(s)
- Armin Ghomeshi
- Urology, Florida International University, Herbert Wertheim College of Medicine, Miami, USA
| | | | - Valencia Henry
- Urology, Edward Via College of Osteopathic Medicine, Spartanburg, USA
| | | | | |
Collapse
|
14
|
Anderson DJ, Lucero M, Vining S, Daniel C, Hasoon J, Viswanath O, Kaye AD, Urits I. Vasectomy Regret or Lack Thereof. Health Psychol Res 2022; 10:38241. [PMID: 36118980 PMCID: PMC9476225 DOI: 10.52965/001c.38241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2023] Open
Abstract
Background Vasectomy is a procedure that results in permanent yet reversible sterility and remains a great contraceptive option for many. Previous research studies have highlighted frequency of vasectomy utilization, defining characteristics of individuals who opt for this method, various surgical techniques, and the risks and benefits associated with the procedure. What remains to be defined is why or why not individuals may experience post-vasectomy regret and whether the previous characteristics correlate. Objective The objective of this review is to synthesize information regarding reasons individuals may regret their vasectomy and seek reversal, what options exist for accomplishing the reversal, and patients' fertility prognosis post-vasovasostomy. Methods This review utilized a combination of secondary and tertiary data analysis across a wide scope of academic databases pertaining to the topic of interest. Results Typically, most males who have sought a vasectomy are satisfied with their decision, however, approximately 6% of this population seeks reversal. Key factors influencing vasectomy regret include age at the time of vasectomy, parental status, pre- and post-operative relationship status, unresolved physical and psychosexual problems, and development of chronic scrotal pain following the procedure. Few options exist for vasectomy reversal including microsurgical reconstructive vasectomy reversal (VR) and sperm extraction for in vitro fertilization. There is no guarantee that fertility will be restored in any case but a major predictive factor for success is the time interval prior to reversal. Conclusion Vasectomy is intended to be a permanent form of contraception; however, a minor chance remains that individuals may experience post-operative regret due to various factors. This warrants proper comprehensive counseling by the patient's provider regarding benefits and risks, procedural outcomes, opportunities for reversal, and fertility prognosis.
Collapse
Affiliation(s)
| | | | | | | | - Jamal Hasoon
- Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
| | - Omar Viswanath
- Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School; Valley Anesthesiology and Pain Consultants, Envision Physician Services; Department of Anesthesiology, University of Arizona College of Medicine Phoenix; Department of Anesthesiology, Creighton University School of Medicine
| | - Alan D Kaye
- Department of Anesthesiology, Louisiana State University Health
| | - Ivan Urits
- Department of Anesthesiology, Louisiana State University Health Shreveport; Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
| |
Collapse
|
15
|
Belardin LB, Légaré C, Sullivan R, Belleannée C, Breton S. Expression of the pro-inflammatory P2Y14 receptor in the non-vasectomized and vasectomized human epididymis. Andrology 2022; 10:1522-1539. [PMID: 36029226 DOI: 10.1111/andr.13284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 08/02/2022] [Accepted: 08/12/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND Vasectomy causes spermatozoa accumulation in the epididymis, which may cause epididymitis. Inflammation is triggered by alert molecules released following tissue stress or injury. These include UDP-glucose, which activates the pro-inflammatory P2Y14 receptor (P2Y14), and induces immune cell recruitment. However, little is known about P2Y14 in the epididymis and its potential activation following vasectomy. OBJECTIVES (i) to localize P2Y14 in the human excurrent duct; and (ii) to examine the effect of vasectomy on P2Y14 protein and P2RY14 mRNA content, the production of selected cytokines and chemokines, and immune cell recruitment in the epididymis. MATERIAL AND METHODS in situ hybridization, qRT-PCR, western blotting, immunohistochemistry and immunofluorescence were performed in banked human epididymis samples. RESULTS P2RY14 mRNA and P2Y14 protein were detected in epithelial cells in the efferent duct, epididymis and vas deferens in non-vasectomized men. Keratin 5 (KRT5)-positive basal cells were strongly labeled for P2Y14 in all epididymal segments. A progressive apical localization was detected in principal cells (negative for the proton pump V-ATPase) from the corpus to the cauda. A subset of V-ATPase-positive clear cells also showed strong P2Y14 labeling. Vasectomy induced an increase in P2RY14 mRNA in the corpus and cauda, and stronger apical labeling in principal cells in the corpus. CXCL10 mRNA increased in the cauda and CCL2 mRNA decreased in the corpus of vasectomized versus non-vasectomized men. No change in IL-8 and IL-1β mRNA was detected. Numerous CD45+ leukocytes were detected in the interstitium of the corpus and cauda following vasectomy, while only a few were seen in non-vasectomized men. Several CD45+ leukocytes, some of which containing spermatozoa, were detected in the corpus lumen following vasectomy. DISCUSSION AND CONCLUSION Our study indicates that vasectomy-induced spermatozoa congestion may lead to an inflamed-prone local environment characterized by potential activation of P2Y14 and recruitment of immune cells in the epididymis. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Larissa Berloffa Belardin
- Centre Hospitalier Universitaire de Québec - Research Centre, Department of Obstetrics, Gynecology and Reproduction, and Centre de Recherche en Reproduction, Développement et Santé Intergénérationnelle, Faculty of Medicine, Université Laval, Québec, QC, Canada
| | - Christine Légaré
- Centre Hospitalier Universitaire de Québec - Research Centre, Department of Obstetrics, Gynecology and Reproduction, and Centre de Recherche en Reproduction, Développement et Santé Intergénérationnelle, Faculty of Medicine, Université Laval, Québec, QC, Canada
| | - Robert Sullivan
- Centre Hospitalier Universitaire de Québec - Research Centre, Department of Obstetrics, Gynecology and Reproduction, and Centre de Recherche en Reproduction, Développement et Santé Intergénérationnelle, Faculty of Medicine, Université Laval, Québec, QC, Canada
| | - Clémence Belleannée
- Centre Hospitalier Universitaire de Québec - Research Centre, Department of Obstetrics, Gynecology and Reproduction, and Centre de Recherche en Reproduction, Développement et Santé Intergénérationnelle, Faculty of Medicine, Université Laval, Québec, QC, Canada
| | - Sylvie Breton
- Centre Hospitalier Universitaire de Québec - Research Centre, Department of Obstetrics, Gynecology and Reproduction, and Centre de Recherche en Reproduction, Développement et Santé Intergénérationnelle, Faculty of Medicine, Université Laval, Québec, QC, Canada
| |
Collapse
|
16
|
Samplaski MK, Rodman JCS, Perry JM, Marks MBF, Zollman R, Asanad K, Marks SF. Sperm granulomas: Predictive factors and impacts on patency post vasectomy reversal. Andrologia 2022; 54:e14439. [PMID: 35524153 PMCID: PMC9541413 DOI: 10.1111/and.14439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/06/2022] [Accepted: 03/18/2022] [Indexed: 12/04/2022] Open
Abstract
The objective of this study was to identify factors that predict for sperm granuloma formation and the impact of sperm granuloma presence and quantity on vasectomy reversal (VR) outcomes. A cross sectional retrospective review of prospectively collected data, on the impact of granuloma on VR outcomes from a single academic center was performed. The impact of age, obstructive interval, intraoperative vasal fluid findings, anastomosis type, body mass index, tobacco use and total motile count (TMC) was determined. A total of 1550 men underwent VR between January 2000 and August 2019. Granulomas were present unilaterally in 23.3% (n = 361) and bilaterally in 14.2% (n = 220). On univariate analysis, increasing patient age negatively correlated with a larger number of granulomas (p = .011). Granuloma presence was associated with finding intact and motile sperm from the vasal stump intraoperatively (p = .001), and vasoepididymostomy anastomosis (p < .001). However, granuloma presence (and quantity) did not correlate with obstructive interval or maximum TMC. Tobacco use and body mass index (BMI) were not associated with granuloma presence. On multivariate analysis, granuloma quantity was not associated with TMC. Obstructive interval and vasovasostomy anastomosis were associated with higher TMC, while BMI was negatively associated with TMC. In conclusion, increasing age was negatively correlated with granuloma formation. Granuloma presence was associated with more favourable intraoperative fluid findings and anastomosis type, but not post-VR TMC, suggesting men with and without granulomas undergoing skilled microsurgery will have similar patency rates. Heavier men should be encouraged for weight loss prior to vasectomy reversal as increasing BMI was associated with lower TMC.
Collapse
Affiliation(s)
- Mary K. Samplaski
- Institute of UrologyUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - John C. S. Rodman
- Southern California Clinical and Translational Science InstituteUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | | | | | - Robert Zollman
- International Center for Vasectomy ReversalTucsonArizonaUSA
| | - Kian Asanad
- Institute of UrologyUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | | |
Collapse
|
17
|
Agarwal A, Gupta S, Sharma RK, Finelli R, Kuroda S, Vij SC, Boitrelle F, Kavoussi P, Rambhatla A, Saleh R, Chung E, Mostafa T, Zini A, Ko E, Parekh N, Martinez M, Arafa M, Tadros N, de la Rosette J, Le TV, Rajmil O, Kandil H, Blecher G, Liguori G, Caroppo E, Ho CCK, Altman A, Bajic P, Goldfarb D, Gill B, Zylbersztejn DS, Molina JMC, Gava MM, Cardoso JPG, Kosgi R, Çeker G, Zilaitiene B, Pescatori E, Borges E, Duarsa GWK, Pinggera GM, Busetto GM, Balercia G, Franco G, Çalik G, Sallam HN, Park HJ, Ramsay J, Alvarez J, Khalafalla K, Bowa K, Hakim L, Simopoulou M, Rodriguez MG, Sabbaghian M, Elbardisi H, Timpano M, Altan M, Elkhouly M, Al-Marhoon MS, Sadighi Gilani MA, Soebadi MA, Nasr-Esfahani MH, Garrido N, Vogiatzi P, Birowo P, Patel P, Javed Q, Ambar RF, Adriansjah R, AlSaid S, Micic S, Lewis SE, Mutambirwa S, Fukuhara S, Parekattil S, Ahn ST, Jindal S, Takeshima T, Puigvert A, Amano T, Barrett T, Toprak T, Malhotra V, Atmoko W, Yumura Y, Morimoto Y, Lima TFN, Kunz Y, Kato Y, Umemoto Y, Colpi GM, Durairajanayagam D, Shah R. Post-Vasectomy Semen Analysis: Optimizing Laboratory Procedures and Test Interpretation through a Clinical Audit and Global Survey of Practices. World J Mens Health 2022; 40:425-441. [PMID: 35021311 PMCID: PMC9253792 DOI: 10.5534/wjmh.210191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 09/16/2021] [Accepted: 09/23/2021] [Indexed: 02/05/2023] Open
Abstract
PURPOSE The success of vasectomy is determined by the outcome of a post-vasectomy semen analysis (PVSA). This article describes a step-by-step procedure to perform PVSA accurately, report data from patients who underwent post vasectomy semen analysis between 2015 and 2021 experience, along with results from an international online survey on clinical practice. MATERIALS AND METHODS We present a detailed step-by-step protocol for performing and interpretating PVSA testing, along with recommendations for proficiency testing, competency assessment for performing PVSA, and clinical and laboratory scenarios. Moreover, we conducted an analysis of 1,114 PVSA performed at the Cleveland Clinic's Andrology Laboratory and an online survey to understand clinician responses to the PVSA results in various countries. RESULTS Results from our clinical experience showed that 92.1% of patients passed PVSA, with 7.9% being further tested. A total of 78 experts from 19 countries participated in the survey, and the majority reported to use time from vasectomy rather than the number of ejaculations as criterion to request PVSA. A high percentage of responders reported permitting unprotected intercourse only if PVSA samples show azoospermia while, in the presence of few non-motile sperm, the majority of responders suggested using alternative contraception, followed by another PVSA. In the presence of motile sperm, the majority of participants asked for further PVSA testing. Repeat vasectomy was mainly recommended if motile sperm were observed after multiple PVSA's. A large percentage reported to recommend a second PVSA due to the possibility of legal actions. CONCLUSIONS Our results highlighted varying clinical practices around the globe, with controversy over the significance of non-motile sperm in the PVSA sample. Our data suggest that less stringent AUA guidelines would help improve test compliance. A large longitudinal multi-center study would clarify various doubts related to timing and interpretation of PVSA and would also help us to understand, and perhaps predict, recanalization and the potential for future failure of a vasectomy.
Collapse
Affiliation(s)
- Ashok Agarwal
- American Center for Reproductive Medicine, Cleveland, OH, USA.
| | - Sajal Gupta
- American Center for Reproductive Medicine, Cleveland, OH, USA
| | - Rakesh K Sharma
- American Center for Reproductive Medicine, Cleveland, OH, USA
| | - Renata Finelli
- American Center for Reproductive Medicine, Cleveland, OH, USA
| | | | - Sarah C Vij
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Florence Boitrelle
- Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France
- Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France
| | - Parviz Kavoussi
- Austin Fertility and Reproductive Medicine/Westlake IVF, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | | | - Ramadan Saleh
- Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt
| | - Eric Chung
- Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia
| | - Taymour Mostafa
- Department of Andrology, Sexology & STIs, Faculty of Medicina, Cairo University, Cairo, Egypt
| | - Armand Zini
- Department of Surgery, McGill University, Montreal, QC, Canada
| | - Edmund Ko
- Department of Urology, Loma Linda University Health, Loma Linda, CA, USA
| | - Neel Parekh
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Marlon Martinez
- Section of Urology, University of Santo Tomas Hospital, Manila, Philippines
| | - Mohamed Arafa
- American Center for Reproductive Medicine, Cleveland, OH, USA
- Department of Urology, Hamad Medical Corporation, Doha, Qatar
- Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar
| | - Nicholas Tadros
- Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA
| | - Jean de la Rosette
- Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey
| | - Tan V Le
- Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Vietnam
- Department of Urology and Andrology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
| | - Osvaldo Rajmil
- Department of Andrology, Fundacio Puigvert, Barcelona, Spain
| | | | - Gideon Blecher
- Department of Surgery, School of Clinical Sciences, Monash University, Melbourne, Australia
| | | | | | - Christopher C K Ho
- Department of Surgery, School of Medicine, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia
| | - Andrew Altman
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Petar Bajic
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - David Goldfarb
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Bradley Gill
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | | | | | - Marcello M Gava
- Sexual and Reproductive Medicine, Department of Urology, Faculdade de Medicina do ABC, Santo André, Brazil
- Andrology Group at Ideia Fertil Institute of Human Reproduction, Santo André, Brazil
| | - Joao Paulo Greco Cardoso
- Divisao de Urologia, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, São Paulo, Brazil
| | - Raghavender Kosgi
- Department of Urology and Andrology, AIG Hospitals, Gachibowli, Hyderabad, India
| | - Gökhan Çeker
- Department of Urology, Samsun Vezirköprü State Hospital, Samsun, Turkey
| | - Birute Zilaitiene
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Edoardo Pescatori
- Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy
| | | | - Gede Wirya Kusuma Duarsa
- Department of Urology, Faculty of Medicine, Sanglah General Academic Hospital, Udayana University, Denpasar, Indonesia
| | | | - Gian Maria Busetto
- Department of Urology and Organ Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy
| | - Giancarlo Balercia
- Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy
| | - Giorgio Franco
- UOC Urologia, Department Materno-Infantile e Scienze Urologiche, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | - Gökhan Çalik
- Department of Urology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Hassan N Sallam
- Department of Obstetrics and Gynaecology, Alexandria University Faculty of Medicine, Alexandria, Egypt
| | - Hyun Jun Park
- Department of Urology, Pusan National University School of Medicine, Busan, Korea
- Medical Research Institute of Pusan National University Hospital, Busan, Korea
| | | | | | | | - Kasonde Bowa
- Department of Urology, School of Medicine and Health Sciences, University of Lusaka, Lusaka, Zambia
| | - Lukman Hakim
- Department of Urology, Universitas Airlangga/Rumah Sakit Universitas Airlangga Teaching Hospital, Surabaya, Indonesia
| | - Mara Simopoulou
- Department of Experimental Physiology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Marcelo Gabriel Rodriguez
- Departamento Docencia e Investigación, Hospital Militar Campo de Mayo, Universidad Barcelo, Buenos Aires, Argentina
| | - Marjan Sabbaghian
- Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | - Haitham Elbardisi
- Department of Urology, Hamad Medical Corporation, Doha, Qatar
- Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar
| | | | - Mesut Altan
- Department of Urology, Hacettepe University, Ankara, Turkey
| | | | | | - Mohammad Ali Sadighi Gilani
- Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | - Mohammad Ayodhia Soebadi
- Department of Urology, Universitas Airlangga/Rumah Sakit Universitas Airlangga Teaching Hospital, Surabaya, Indonesia
| | - Mohammad Hossein Nasr-Esfahani
- Department of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
| | - Nicolas Garrido
- IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain
| | - Paraskevi Vogiatzi
- Andromed Health & Reproduction, Fertility Diagnostics Laboratory, Maroussi, Greece
| | - Ponco Birowo
- Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
| | - Premal Patel
- Section of Urology, University of Manitoba, Winnipeg, MB, Canada
| | - Qaisar Javed
- Department of Urology, Ahalia Hospital, Hamdan Street Branch, Abu Dhabi, UAE
| | - Rafael F Ambar
- Andrology Group at Ideia Fertil Institute of Human Reproduction, Santo André, Brazil
- Department of Urology, Centro Universitario em Saude do ABC, Santo André, Brazil
| | - Ricky Adriansjah
- Department of Urology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia
| | - Sami AlSaid
- Department of Urology, Hamad Medical Corporation, Doha, Qatar
| | - Sava Micic
- Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia
| | - Sheena E Lewis
- Examenlab Ltd., Weavers Court Business Park, Linfield Road, Belfast, Northern Ireland, UK
| | - Shingai Mutambirwa
- Division of Urology, Safeko Makgatho Health Scienses University and Dr George Mukhari Academic Hospital, Pretoria, South Africa
| | - Shinichiro Fukuhara
- Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Sijo Parekattil
- Avant Concierge Urology & University of Central Florida, Winter Garden, FL, USA
| | - Sun Tae Ahn
- Department of Urology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
| | - Sunil Jindal
- Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India
| | - Teppei Takeshima
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Ana Puigvert
- Fundació Puigvert, Hospital de la Santa Cruz y San Pablo, Universidad Autonoma de Barcelona, Barcelona, Spain
| | - Toshiyasu Amano
- Department of Urology, Nagano Red Cross Hospital, Nagano, Japan
| | | | - Tuncay Toprak
- Department of Urology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey
| | - Vineet Malhotra
- Department of Andrology and Urology, Diyos Hospital, New Delhi, India
| | - Widi Atmoko
- Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
| | - Yasushi Yumura
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | | | | | - Yannic Kunz
- Department of Urology, Innsbruck Medical University, Innsbruck, Austria
| | - Yuki Kato
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Yukihiro Umemoto
- Department of Nephro-Urology, Nagoya City West Medical Center, Nagoya, Japan
| | | | - Damayanthi Durairajanayagam
- Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia
| | - Rupin Shah
- Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India
| |
Collapse
|
18
|
Zini A, Grantmyre J, Chow V, Chan P. UPDATE - 2022 Canadian Urological Association best practice report: Vasectomy. Can Urol Assoc J 2022; 16:E231-E236. [PMID: 35544354 PMCID: PMC9119596 DOI: 10.5489/cuaj.7860] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Affiliation(s)
- Armand Zini
- Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada
| | - John Grantmyre
- Department of Urology, Dalhousie University, Halifax, NS, Canada
| | - Victor Chow
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Peter Chan
- Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada
| |
Collapse
|
19
|
Lang JJ, Giffen Z, Hong S, Demeter J, El-Zawahry A, Sindhwani P, Ekwenna O. Assessing Vasectomy-Related Information on YouTube: An Analysis of the Quality, Understandability, and Actionability of Information. Am J Mens Health 2022; 16:15579883221094716. [PMID: 35491867 PMCID: PMC9066630 DOI: 10.1177/15579883221094716] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
This study aims to critically appraise the quality of vasectomy-related health information currently available on YouTube to better address patient information needs moving forward. A YouTube search was performed using the keyword “vasectomy.” The first 100 videos were assessed, with irrelevant and duplicate videos excluded. Two independent reviewers evaluated the remaining videos using the DISCERN instrument for evaluating the quality of information and the Patient Education Materials Assessment Tool for Audiovisual materials (PEMAT-A/V) for assessing the understandability and actionability of materials. Source characteristics and markers of bias and misinformation were also collected. Seventy-eight videos were included in the study, with a mean duration of 6.6 minutes and mean of 216,672 views. The median DISCERN score was poor at 28 (IQR 22–33) out of a possible 80 with mean PEMAT-AV Understandability and Actionability scores of 67.6% (±16.7%) and 33.8% (±36.2%), respectively. A medical doctor was present in 61 (78.2%) of the videos, of which 53 (86.9%) were urologists and 38 (62.2%) promoted their personal practice or institution. False statements regarding vasectomy were made in 14 (17.9%) videos. Notably, no significant difference was noted in quality, understandability, or actionability of videos created by those with personal promotion to those without. The quality of information regarding vasectomy on YouTube is poor and reaches a wide audience. Continued appraisal and creation of YouTube videos that contain quality, understandable and actionable information by urologists is necessary to ensure patients are well-informed.
Collapse
Affiliation(s)
- Jacob J. Lang
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Zane Giffen
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Department of Urology and Transplantation, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Stephen Hong
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Jonathan Demeter
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Department of Urology and Transplantation, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Ahmed El-Zawahry
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Department of Urology and Transplantation, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Puneet Sindhwani
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Department of Urology and Transplantation, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Puneet Sindhwani, Department of Urology and Transplantation, College of Medicine and Life Sciences, The University of Toledo, 3000 Arlington Avenue, Mailstop 1091, Toledo, OH 43614, USA.
| | - Obi Ekwenna
- University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Department of Urology and Transplantation, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| |
Collapse
|
20
|
Recent progress in advanced biomaterials for long-acting reversible contraception. J Nanobiotechnology 2022; 20:138. [PMID: 35300702 PMCID: PMC8932341 DOI: 10.1186/s12951-022-01329-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 02/28/2022] [Indexed: 12/15/2022] Open
Abstract
Unintended pregnancy is a global issue with serious ramifications for women, their families, and society, including abortion, infertility, and maternal death. Although existing contraceptive strategies have been widely used in people's lives, there have not been satisfactory feedbacks due to low contraceptive efficacy and related side effects (e.g., decreased sexuality, menstrual cycle disorder, and even lifelong infertility). In recent years, biomaterials-based long-acting reversible contraception has received increasing attention from the viewpoint of fundamental research and practical applications mainly owing to improved delivery routes and controlled drug delivery. This review summarizes recent progress in advanced biomaterials for long-acting reversible contraception via various delivery routes, including subcutaneous implant, transdermal patch, oral administration, vaginal ring, intrauterine device, fallopian tube occlusion, vas deferens contraception, and Intravenous administration. In addition, biomaterials, especially nanomaterials, still need to be improved and prospects for the future in contraception are mentioned.
Collapse
|
21
|
Atkinson M, James G, Bond K, Harcombe Z, Labrecque M. Comparison of postal and non-postal post-vasectomy semen sample submission strategies on compliance and failures: an 11-year analysis of the audit database of the Association of Surgeons in Primary Care of the UK. BMJ SEXUAL & REPRODUCTIVE HEALTH 2022; 48:54-59. [PMID: 34321257 DOI: 10.1136/bmjsrh-2021-201064] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 07/13/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND Vasectomy occlusive success is defined by the recommendation of 'clearance' to stop other contraception, and is elicited by post-vasectomy semen analysis (PVSA). We evaluated how the choice of either a postal or non-postal PVSA submission strategy was associated with compliance to PVSA and effectiveness of vasectomy. METHODS We studied vasectomies performed in the UK from 2008 to 2019, reported in annual audits by Association of Surgeons in Primary Care members. We calculated the difference between the two strategies for compliance with PVSA, and early and late vasectomy failure. We determined compliance by adding the numbers of men with early failure and those given clearance. We performed stratified analyses by the number of test guidance for clearance (one-test/two-test) and the study period (2008-2013/2014-2019). RESULTS Among 58 900 vasectomised men, 32 708 (56%) and 26 192 (44%) were advised submission by postal and non-postal strategies, respectively. Compliance with postal (79.5%) was significantly greater than with non-postal strategy (59.1%), the difference being 20.4% (95% CI 19.7% to 21.2%). In compliant patients, overall early failure detection was lower with postal (0.73%) than with non-postal (0.94%) strategy (-0.22%, 95% CI -0.41% to -0.04%), but this difference was neither clinically nor statistically significant with one-test guidance in 2014-2019. There was no difference in late failure rates. CONCLUSIONS Postal strategy significantly increased compliance to PVSA with similar failure detection rates. This resulted in more individuals receiving clearance or early failure because of the greater percentage of postal samples submitted. Postal strategy warrants inclusion in any future guidelines as a reliable and convenient option.
Collapse
Affiliation(s)
- Melanie Atkinson
- Sexual & Reproductive Health, Aneurin Bevan University Health Board, Newport, UK
| | - Gareth James
- Audit Lead for Association of Surgeons in Primary Care (ASPC), Rugby, UK
| | - Katie Bond
- Palliative Care, Aneurin Bevan University Health Board, Newport, UK
| | | | - Michel Labrecque
- Department of Family and Emergency Medicine Laval University and Research Center, CHU de Québec-Université Laval, Quebec, Quebec, Canada
| |
Collapse
|
22
|
Zhang X, Eisenberg ML. Vasectomy utilization in men aged 18-45 declined between 2002-2017: Results from the United States National Survey for Family Growth Data. Andrology 2021; 10:137-142. [PMID: 34390207 DOI: 10.1111/andr.13093] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 06/20/2021] [Accepted: 07/23/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Vasectomy remains a safe, simple and effective contraceptive options. Conflicting data on the trend of vasectomy use among men have been described previously at various snapshots in time over the last two decades. OBJECTIVES This paper seeks to describe the trend of vasectomy utilization in the last 15 years using a nationally representative United States survey. MATERIALS AND METHODS We analyzed data from male respondents aged 18 to 45 years of the Cycle 6 (2002), 2006-2010, 2011-2013, 2013-2015, and 2015-2017 National Survey of Family Growth (NSFG) surveys. Population estimates are calculated based on the official NSFG instructions, accounting for the complex survey design. Multivariate logistic regression models are used to study demographic and socioeconomic factors associated with vasectomy use in men. RESULTS Baseline characteristics for men undergoing vasectomy do not differ significantly across survey years. Increased age, White race, marital status, higher education level, birthplace within the United States, higher household income, non-Catholic affiliation, and higher number of biological kids have significant positive associations with vasectomy use. After accounting for factors associated with vasectomy utilization, there was a significant temporal decline in vasectomy utilization rates in all age groups across survey years which remained in subgroup analyses of all men greater than 25, 30, and 35 of age. DISCUSSION This is the first population-based analysis of US data to observe a decline in vasectomy utilization over the past two decades. The decline was statistically significant after accounting for all demographic and socioeconomic factors. CONCLUSION There is a steady decline in the prevalence of vasectomy use in men from 2002 to 2017. Given the limited contraceptive options for men and the importance of contraception and family planning in the US, further research is needed to understand the temporal decline. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Xinyuan Zhang
- Department of Urology, Stanford University School of Medicine, Stanford, California, 94305, USA
| | - Michael L Eisenberg
- Department of Urology, Stanford University School of Medicine, Stanford, California, 94305, USA
| |
Collapse
|
23
|
Pennings G, Couture V, Ombelet W. Social sperm freezing. Hum Reprod 2021; 36:833-839. [PMID: 33501976 DOI: 10.1093/humrep/deaa373] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 12/17/2020] [Indexed: 12/31/2022] Open
Abstract
Increased paternal age has been associated with lower fertility and higher genetic risk for the offspring. One way to prevent these consequences is to freeze sperm at a young age. Social sperm freezing could be developed in a way similar to social oocyte freezing. The main difference between freezing oocytes and sperm is that social sperm freezing is much less focussed on fertility preservation and much more on avoiding increased genetic risk. Contrary to what some people seem to believe, sperm freezing is more complicated than it looks at first sight. This article considers three practical aspects: freezing, storage and testing. It is concluded that the remedy (cryopreservation) may itself cause damage to the quality of the spermatozoon and to its genetic integrity, thus undoing the possible benefits in terms of fertility and health of offspring.
Collapse
Affiliation(s)
- Guido Pennings
- Department of Philosophy and Moral Science, Bioethics Institute Ghent (BIG), Ghent University, Ghent B-9000, Belgium
| | - Vincent Couture
- Faculty of Nursing, Université Laval, Québec, QC G1V 0A6, Canada.,Research Center of the CHU de Québec-Université Laval, Québec, QC G1L 3L5, Canada
| | - Willem Ombelet
- Genk Institute for Fertility Technology, ZOL Hospitals, Genk B-3600, Belgium.,Faculty of Medicine and Life Sciences, Hasselt University, Hasselt B-3500, Belgium
| |
Collapse
|
24
|
[Vasectomy : Current information]. Urologe A 2021; 60:523-532. [PMID: 33738559 DOI: 10.1007/s00120-021-01494-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/16/2021] [Indexed: 10/21/2022]
Abstract
Vasectomy is considered to be the simplest, most effective and cheapest method of fertility control in men, with a significantly lower risk of morbidity and mortality compared to tubal ligation in women. Patient informed consent is particularly important and should include potential irreversibility, surgical options, anesthesia, possible complications as well as postoperative behavior and the need for re-evaluation. There are different access routes available with conventional and no-scalpel vasectomy as well as different techniques for closing the ends of the vas deferens. To confirm sterility the European Association of Urology (EAU) recommends that an ejaculate analysis should be performed 3 months after the procedure and after approximately 20 ejaculations. Complications are relatively rare, although particularly vasectomy failure due to recanalization has to be considered. Approximately 3-6% of vasectomized men strive for a refertilization, which with experienced surgeons is successful in about 90% of cases.
Collapse
|
25
|
Gashaye KT, Tsegaye AT, Abebe SM, Woldetsadik MA, Ayele TA, Gashaw ZM. Determinants of long acting reversible contraception utilization in Northwest Ethiopia: An institution-based case control study. PLoS One 2020; 15:e0240816. [PMID: 33079973 PMCID: PMC7575092 DOI: 10.1371/journal.pone.0240816] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 10/02/2020] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Though long-acting reversible contraceptives (LARCs) are highly effective, have minimal side effects, require minimal follow-up, and are low cost, only 10% of contraceptives used in Ethiopia are LARCs. The reason for this low uptake is not understood at the country or regional level. Therefore, this study identified determinants of LARC utilization in Northwest Ethiopia. METHODS A facility-based unmatched case control study, using LARC users as cases and short- acting reversible contraception (SARC) users as controls, had been conducted at fourteen public health institutions in Northwest Ethiopia. A systematic random sampling technique was used to select participants with a 1:2 case to control ratio (n = 1167). Binary logistic regression analysis was used to identify determinants of LARC utilization among family planning service users. RESULTS Wealth status [AOR:1.87, 95%CI (1.08, 3.24)], history of abortion [AOR:2.69, 95%CI (1.41, 5.12)], limiting family size [AOR: 2.38, 95%CI (1.01, 5.62)], good knowledge about LARCs [AOR: 2.52, 95%CI (1.17, 5.41)], method convenience [AOR: 0.23, 95%CI (0.16, 0.34)], good availability of method [AOR:0.10 (0.05, 0.19)], less frequent visits to health facility [AOR:2.95, 95% CI(1.89, 4.62)], health care providers advice [AOR:10.69, 95%CI (3.27, 34.87)], partner approval [AOR:0.66, 95%CI (0.45, 0.97)], and favorable attitude towards LARCs [AOR:13.0, 95%CI (8.60, 19.72)] were significantly associated with LARC utilization. CONCLUSION Professional support, favorable attitude towards LARC use, high economic status, history of abortion, advantage of less frequent visits, having good knowledge towards LARC and interest of limiting births were significantly associated with LARC Utilization. On the other hand, perceived method convenience, and contraception availability were inversely associated with it. Family planning education about the benefits of LARC should be done by health providers and media. Male involvement in the counselling and decision making about the advantage of using LARC may improve the negative influence of partners on LARC utilization. It is also recommended that, future qualitative research further explore perceptions of LARC use.
Collapse
Affiliation(s)
- Kiros Terefe Gashaye
- Department of Obstetrics and Gynecology, College of Medicine and Health Sciences, School of Medicine, University of Gondar, Gondar, Ethiopia
| | - Adino Tesfahun Tsegaye
- Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Solomon Mekonnen Abebe
- Department of Nutrition, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Mulat Adefris Woldetsadik
- Department of Obstetrics and Gynecology, College of Medicine and Health Sciences, School of Medicine, University of Gondar, Gondar, Ethiopia
| | - Tadesse Awoke Ayele
- Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Zelalem Mengistu Gashaw
- Department of Obstetrics and Gynecology, College of Medicine and Health Sciences, School of Medicine, University of Gondar, Gondar, Ethiopia
| |
Collapse
|
26
|
Sooltangos A, Al-Ausi M. Local anaesthetic vasectomy is not as painful as patients expect. BMJ SEXUAL & REPRODUCTIVE HEALTH 2020; 46:234-235. [PMID: 31879334 DOI: 10.1136/bmjsrh-2019-200462] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
| | - Maher Al-Ausi
- General Practice Surgery, Marple Cottage Surgery, Manchester, UK
| |
Collapse
|
27
|
Khilwani B, Badar A, Ansari AS, Lohiya NK. RISUG ® as a male contraceptive: journey from bench to bedside. Basic Clin Androl 2020; 30:2. [PMID: 32082579 PMCID: PMC7017607 DOI: 10.1186/s12610-020-0099-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 01/13/2020] [Indexed: 11/10/2022] Open
Abstract
Even after decades of research men still lack reliable and reversible contraceptive methods comparable to female methods of contraception. Traditional methods of male contraception present a high failure rate and also involve high risk both when used for contraception and for protection against sexually transmitted diseases. Various chemical, hormonal, immunological, vas based and herbal methods of contraception have been examined by scientists world over during the past four decades. Among the possible lead approaches, exogenous hormonal contraception, either alone or in combination with progesterone or antiandrogen, is being viewed at low profile because of their insufficiency in inducing uniform suppression of spermatogenesis and steroid related long term complications. As an alternative to vasectomy, among various intravasal devices being examined, RISUG® (Reversible Inhibition of Sperm Under Guidance), a co-polymer of styrene and maleic anhydride offers long term contraception with safety, efficacy and it can be delivered by no-scalpel injection. Thus it is the only male contraceptive procedure currently under Phase- III Clinical Trial. The non-invasive reversal technique, successfully demonstrated in langur monkeys and functional reversal achieved with dimethyl sulphoxide (DMSO) and sodium bicarbonate (NaHCO3) in rats and rabbits with safety at F1 generation (first filial generation) have projected RISUG® as a better alternative to vasectomy. In this narrative review we revisit the long journey of RISUG® beginning with formulation on a bench towards reaching the market as a safe and effective contraceptive method, discussing various milestones and roadblocks of this expedition awaiting the mandatory regulatory clearance from the Government of India. Successful completion of ongoing phase III clinical trials with demonstration of reversal in human volunteers will give an indigenously developed male contraceptive to the world.
Collapse
Affiliation(s)
- Barkha Khilwani
- Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, 302004 India
| | - Ayesha Badar
- Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, 302004 India
| | - Abdul S. Ansari
- Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, 302004 India
| | - Nirmal K. Lohiya
- Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, 302004 India
| |
Collapse
|
28
|
Kern T, Artenstein D, Shapiro C. Postvasectomy Scrotal Pain and Hematospermia, a Possible Harbinger for Vasectomy Failure and Recanalization: A Case Report. Perm J 2019; 24:19.068. [PMID: 31710838 DOI: 10.7812/tpp/19.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Vasectomy is the most common and most effective method of achieving permanent male sterility. However, there is a low risk of vasectomy failure. To our knowledge, there is no symptom complex that has been identified and described that is predictive of early recanalization and vasectomy failure. CASE PRESENTATION A 44-year-old man underwent a routine bilateral vasectomy without complication. Two months after the procedure, the patient experienced an acute onset of scrotal pain and hematospermia. Several semen analyses were performed during the following months, the results of which demonstrated progressively rising numbers of motile sperm and were indicative of vasal recanalization. The patient underwent repeated vasectomy, during which he was found to have right vasal recanalization leading to vasectomy failure. DISCUSSION Delayed postvasectomy scrotal pain associated with hematospermia may be a sign of vasal recanalization. We propose that this symptom complex should prompt an investigation for vasal recanalization, during which the patient should be instructed to refrain from intercourse without the use of an additional method of contraception.
Collapse
Affiliation(s)
- Tyler Kern
- Department of Urology, Kaiser Permanente Los Angeles Medical Center, CA
| | - Daniel Artenstein
- Department of Urology, Kaiser Permanente Los Angeles Medical Center, CA
| | - Charles Shapiro
- Department of Urology, Kaiser Permanente Los Angeles Medical Center, CA
| |
Collapse
|
29
|
Gray RE, Kasper K. Osteopathic Manipulative Treatment as a Novel Way to Manage Postvasectomy Pain Syndrome. J Osteopath Med 2018; 119:2712171. [PMID: 30383152 DOI: 10.7556/jaoa.2018.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Postvasectomy pain syndrome (PVPS) can be debilitating and is notoriously difficult to treat, often requiring a multidisciplinary approach. In this case report, osteopathic manipulative treatment (OMT) was used to treat a patient with PVPS. After vasectomy, an otherwise-healthy man experienced chronic right testicular pain, aggravated by exercise, touch, and sexual intercourse, resulting in marital strain and an inability to perform routine fitness activities. Symptoms persisted for 8 years, despite lifestyle modifications, orally administered pain regimens, pelvic floor physical therapy, nerve blocks, steroid injections, epididymectomy, spermatic cord denervation, and counseling. After the patient's urologist suggested orchiectomy, his family medicine physician referred him for OMT. The OMT interventions, applied over a 4-month period, were directed at the lumbar spine, pelvis, pelvic floor, and lower abdomen. After treatment, the patient reported absence of testicular pain most of the time and described his quality of life as "10 times better." Literature review revealed no reports of OMT used to manage PVPS.
Collapse
|
30
|
Zhao K, Wu L, Kong X, Chen Y, Li H, Gu Y, Shang X, Xiong C. Long-term safety, health and mental status in men with vasectomy. Sci Rep 2018; 8:15703. [PMID: 30356207 PMCID: PMC6200721 DOI: 10.1038/s41598-018-33989-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Accepted: 10/10/2018] [Indexed: 11/09/2022] Open
Abstract
Vasectomy is an efficient male contraceptive method, but the long-term effects of this technology in a large population are unclear. To investigate the influence of vasectomy on long-term health effects, we recruited 485 men with a vasectomy and 1940 men without vasectomy in China. After obtaining basic information from the Aging Males’ Symptoms (AMS) scale and other questionnaires, peripheral blood was drawn to assess the hormone levels, prostate specific antigen (PSA) and blood biochemistry. Using multiple linear regression analysis, these factors had no relationship with vasectomy except for four factors including the Somatic score (0.31, 0.02 and 0.61) in AMS, SF-36 score (−18.8, −32.00 and −5.60), “Role emotional” (−6.28, −10.34 and −2.22) and “Mental health” (−1.55, −3.08 and −0.02). A stratified analysis showed that with increased age, smoking and drinking, residence in township or a higher level of education, the mental health of men was worse. Vasectomy had no long-term effect on the level of sexual hormones in men, and it did not increase the level of PSA. The impact of the vasectomy on quality of life in men were mainly reflected in psychological effects, which suggests that men with vasectomy groups many benefit from professional psychological counseling.
Collapse
Affiliation(s)
- Kai Zhao
- Center of Reproductive Medicine, Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Li Wu
- Center of Reproductive Medicine, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Xiangbin Kong
- Center of Reproductive Medicine, Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Yaoping Chen
- Center of Reproductive Medicine, Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Honggang Li
- Center of Reproductive Medicine, Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Yiqun Gu
- National Health and Family Planning Key Laboratory of Male Reproductive Health, National Research Institute for Family Planning, Beijing, China
| | - Xuejun Shang
- Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
| | - Chengliang Xiong
- Center of Reproductive Medicine, Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. .,Wuhan Tongji Reproductive Medicine Hospital, Wuhan, China.
| |
Collapse
|
31
|
Vasectomy with vessel sealing device: comparison of different diameters. Int J Impot Res 2018; 31:20-24. [PMID: 30154455 DOI: 10.1038/s41443-018-0066-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 06/25/2018] [Accepted: 08/06/2018] [Indexed: 11/08/2022]
Abstract
OBJECTIVES Vasectomy is a popular and effective male surgical contraceptive method. Different techniques have been proposed to reduce failure rates and complications. In this study, we sought to compare vas deferens occlusion rates using both standard occlusion techniques and LigaSure (LSVS) for vasectomy. MATERIAL AND METHODS A total of nine patients underwent open radical retropubic prostatectomy at our institution. During the procedure, a total of 125 fresh vas deferens samples were obtained and divided into four groups as follows: Group 1: ligation (n = 22), Group 2; ligation and electrocauterization (n = 18), Group 3; 5 mm LSVS (n = 44), Group 4; 10 mm LSVS (n = 41). All specimens were harvested during surgery and subsequent histopathological assessments were performed to assess the luminal status of the vas deferens. RESULTS Histopathological evaluation revealed that the majority of vas lumens with LSVS (79.5% of Group 3 and 89.4% of Group 4) were totally occluded. With standard techniques, however, the majority of vas lumens (86.4 and 77.8% of Groups 1 and 2, respectively) maintained a tiny patency. CONCLUSIONS On histopathological review, the application of LSVS resulted in better occlusion rates, compared to standard ligation methods. These findings suggest a higher occlusive role for LSVS for vasectomy. Further clinical studies are needed to confirm the clinical efficacy and safety of this technique.
Collapse
|
32
|
Frankiewicz M, Połom W, Matuszewski M. Can the evolution of male contraception lead to a revolution? Review of the current state of knowledge. Cent European J Urol 2018; 71:108-113. [PMID: 29732216 PMCID: PMC5926633 DOI: 10.5173/ceju.2017.1450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 12/17/2017] [Accepted: 12/22/2017] [Indexed: 11/22/2022] Open
Abstract
Introduction Great advances in medical research concerning methods of contraception have been achieved in recent years, however, more than 25% of couples worldwide still rely on condoms - a method with poor efficacy. Even though there is a spectrum of 11 different contraceptive methods for women, there are only 4 commonly used by men (condoms, periodic abstinence, withdrawal and vasectomy). In this review, advances and present, state-of-the-art, both hormonal and non-hormonal male contraceptive methods will be presented and evaluated. Potential novel targets that warrant greater research will be highlighted. Material and methods A comprehensive literature search without a time limit was performed using the Medline database on May 2017. The terms 'male contraception' in conjunction with 'reversible inhibition of sperm under guidance' (RISUG), 'hormonal', 'non-hormonal', 'vasectomy' or 'testosterone' were used. The articles were limited to those published in English, Polish or French. Results There are various contraceptives currently available to regulate male fertility. Vasectomy is still the most effective permanent form of male contraceptive with a failure rate lower than 1%. Reversible, non hormonal methods of male contraception, like reversible inhibition of sperm under guidance, are very promising and close to being introduced into the market. In regards to hormonal contraception research, the use of testosterone injections has been widely studied yet they often harbor undesirable side effects and require further development. Conclusions Despite continuous efforts worldwide, it seems that another several years of research is needed to provide safe, effective and affordable male contraceptives which will allow both men and women to participate fully in family planning.
Collapse
Affiliation(s)
| | - Wojciech Połom
- Department of Urology Medical University of Gdańsk, Gdańsk, Poland
| | | |
Collapse
|
33
|
Tan WP, Tsambarlis PN, Levine LA. Microdenervation of the spermatic cord for post-vasectomy pain syndrome. BJU Int 2018; 121:667-673. [PMID: 29352521 DOI: 10.1111/bju.14125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To evaluate the outcomes of patients who underwent microdenervation of the spermatic cord (MDSC) for post-vasectomy pain syndrome (PVPS) at our institution. METHODS A retrospective study of all patients who underwent MDSC for PVPS by a single surgeon between March 2002 and October 2016 was performed. Pain was documented using the numerical rating scale (NRS). Spermatic cord block (SCB) was performed on all patients, and success was defined as NRS score ≤1 for >4 h. All patients had failed medical therapy prior to MDSC. All previous procedures for PVPS had been performed elsewhere. Surgical success was defined as a postoperative NRS score of ≤1. RESULTS A total of 27 patients with 28 scrotal units underwent MDSC for PVPS. The median (1st quartile; 3rd quartile) follow-up was 10 (2; 16.5) months. The median (range) duration of pain prior to surgery was 57 (8-468) months. Pain was bilateral in 14 (52%), left-sided in eight (30%) and right-sided in five patients (19%). Data on SCB were available for 23 patients, with a success rate of 96%. The median (range) preoperative pain NRS score was 7 (2-10). The median (range) pain score after SCB on the NRS scale was 0 (0-5). The median (range) postoperative pain score on the NRS was 0 (0-9). Overall success was achieved in 20 of 28 testicular units (71%). Patients with involvement of multiple structures in the scrotum (i.e. testis, epididymis, spermatic cord) had a success rate of 81% and were more likely to have a successful surgery (P < 0.001). Five patients had failed a prior epididymectomy and three had failed a vaso-vasostomy for PVPS; this had no correlation with the success of MDSC (P = 0.89). CONCLUSION The MDSC procedure is a reasonably successful, durable and valuable approach for PVPS, especially when pain involves multiple structures in the scrotum (testis, epididymis, spermatic cord). MDSC was equally efficacious in patients who had previously failed a procedure for PVPS. No patient had a worsening NRS score after MDSC. This is the largest study to date evaluating MDSC for the treatment of PVPS.
Collapse
Affiliation(s)
- Wei Phin Tan
- Division of Urology, Rush University Medical Center, Chicago, IL, USA
| | | | - Laurence A Levine
- Division of Urology, Rush University Medical Center, Chicago, IL, USA
| |
Collapse
|
34
|
HIGH PREVALENCE OF VOLUNTARY STERILIZATION AMONG AMERICAN WOMEN EXPLAINED BY TRADE-OFFS RESULTING FROM MALE PARENTAL COMMITMENT. J Biosoc Sci 2017; 50:505-526. [PMID: 28879818 DOI: 10.1017/s0021932017000414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Tubal ligation is the modal form of family planning among American women aged 30 and older. As the preference for tubal ligation over cheaper, lower risk and more reliable methods, such as vasectomy, has puzzled experts, a theoretical approach that explains this preference would be useful. The present study investigates the high prevalence of voluntary sterilization among American women from the perspective of life history theory, arguing that the trade-offs between investing in current and future offspring will favour tubal ligation when women cannot obtain reliable male commitment to future parental investment. Data came from the National Survey of Fertility Barriers (NSFB), a nationally representative survey of 4712 American women aged 25-45 conducted between 2004 and 2007. Four novel predictions of the prevalence of tubal ligation, drawn from life history theory, were developed and tested: 1) it is most common among unpartnered women with children, and least common among married women with children; 2) it is negatively correlated with age at first birth; 3) it is least common among highly educated women without children, and most common among less educated women with children; and 4) among women with two or more children, it is positively correlated with lifetime number of long-term partners. These predictions were tested using multivariate regression analysis. The first prediction was not supported: women with children were more likely to be sterilized, regardless of their marital status. The other three predictions were all supported by the data. The results suggest that trade-offs influence women's decisions to undergo voluntary sterilization. Women are most likely to opt for tubal ligation when the costs of an additional child will impinge on their ability to invest in existing offspring, especially in the context of reduced male commitment.
Collapse
|
35
|
Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, Barbieri CE. Vasectomy and Risk of Prostate Cancer in a Screening Trial. Cancer Epidemiol Biomarkers Prev 2017; 26:1653-1659. [PMID: 28830873 DOI: 10.1158/1055-9965.epi-16-0776] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 12/30/2016] [Accepted: 08/11/2017] [Indexed: 11/16/2022] Open
Abstract
Background: Vasectomy has been implicated as a risk factor for prostate cancer in multiple epidemiologic studies over the past 25 years. Whether this relationship is causal remains unclear. This study examines the association between vasectomy and prostate cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, which randomized men to usual care or annual prostate cancer screening.Methods: We performed a retrospective analysis of 13-year screening and outcomes data from the PLCO trial. Multivariable Cox proportional hazards regression stratified by study arm and age at vasectomy was performed.Results: There was an increased risk of prostate cancer in men who had undergone a vasectomy and were randomized to the usual care arm of the study (adjusted HR, 1.11; 95% confidence interval, 1.03-1.20; P = 0.008). There was no association between vasectomy and diagnosis of prostate cancer in men randomized to the prostate cancer screening arm. Only men undergoing vasectomy at an older age in the usual care arm of the study, but not the prostate cancer screening arm, were at increased risk of being diagnosed with prostate cancer.Conclusions: Vasectomy was not associated with prostate cancer risk among men who were screened for prostate cancer as part of a clinical trial, but was associated with prostate cancer detection in men receiving usual care.Impact: The positive association between vasectomy and prostate cancer is likely related to increased detection of prostate cancer based on patterns of care rather than a biological effect of vasectomy on prostate cancer development. Cancer Epidemiol Biomarkers Prev; 26(11); 1653-9. ©2017 AACR.
Collapse
Affiliation(s)
- Jonathan Shoag
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York.
| | - Oleksander Savenkov
- Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York
| | - Paul J Christos
- Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York
| | - Sameer Mittal
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Joshua A Halpern
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Gulce Askin
- Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York
| | - Daniel Shoag
- Department of Public Policy, Harvard Kennedy School, Cambridge, Massachusetts
| | - Ron Golan
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Daniel J Lee
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Padraic O'Malley
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York.,Department of Urology, Dalhousie University, Halifax, Nova Scotia
| | - Bobby Najari
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Brian Eisner
- Department of Urology, Massachusetts General Hospital, Boston, Massachusetts
| | - Jim C Hu
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Douglas Scherr
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Peter Schlegel
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
| | - Christopher E Barbieri
- Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York.,Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, New York
| |
Collapse
|
36
|
Guo ZL, Xu JL, Lai RK, Wang SS. Vasectomy and cardiovascular disease risk: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96:e7852. [PMID: 28834896 PMCID: PMC5572018 DOI: 10.1097/md.0000000000007852] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 07/05/2017] [Accepted: 07/31/2017] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND Even though several studies comparing vasectomy and cardiovascular disease (CVD) risk have been reported, most are small series with conflicting results. However, the extent of the risk is still uncertain. We therefore explored whether an association exists between vasectomy and CVD incidence and mortality. METHODS We searched PubMed, Embase, Web of Science, and Cochrane Library databases for relevant studies published before January 2017. Multivariate adjusted odds ratio (OR) and associated 95% confidence intervals (CIs) and those by subgroups were extracted and pooled using random-effects models. RESULTS Overall, 12 observational studies (2 cross-sectional studies, 4 case-control studies, and 6 retrospective cohort studies) comprising 299,436 participants were identified. There was no statistically significant relationship between vasectomy and CVD risk (OR: 0.90, 95% CI: 0.81-1.00). Moreover, vasectomy was not associated with CVD mortality (OR: 0.90, 95% CI: 0.81-1.00), coronary heart disease (CHD) incidence (OR: 0.94, 95% CI: 0.88-1.01), stroke incidence (OR: 0.90, 95% CI: 0.72-1.13), and myocardial infarction (MI) incidence (OR: 0.95, 95% CI: 0.88-1.02), with no significant publication bias. In subgroup analyses, the findings on the association between vasectomy and CVD risk were consistent. CONCLUSION Our findings suggest that vasectomy is not associated with the excess risk of CVD incidence and mortality. Nevertheless, large-volume, well-designed observational studies, with different ethnic populations, low risk of bias, and adjusted confounding factors, are awaited to confirm and update the findings of this analysis.
Collapse
Affiliation(s)
- Zhen-Lang Guo
- The Second Clinical College, Guangzhou University of Chinese Medicine
| | - Jing-Li Xu
- The Second Clinical College, Guangzhou University of Chinese Medicine
| | | | - Shu-Sheng Wang
- Department of Urology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
| |
Collapse
|
37
|
Abstract
Post-vasectomy pain syndrome (PVPS) is a rare, but devastating outcome following vasectomy. Given the widespread utilization of vasectomy for permanent contraception, with more than 500,000 procedures performed annually in the United States, it can be a significant challenge for both patients and providers. Vasectomy reversal is a surgical option for men who fail conservative or medical management. Despite improvements in technique, vasectomy carries some inherent risks making pre-procedure counseling regarding the risks of PVPS paramount. Chronic post-operative pain, or PVPS, occurs in 1-2% of men undergoing the procedure. This review will examine the utility of vasectomy reversal as a means of addressing PVPS.
Collapse
Affiliation(s)
- L I Smith-Harrison
- Department of Urology, University of Virginia Health System, Charlottesville, VA 22908, USA
| | - Ryan P Smith
- Department of Urology, University of Virginia Health System, Charlottesville, VA 22908, USA
| |
Collapse
|
38
|
Smith K, Byrne, Castaño JM, Chirlaque MD, Lilja H, Agudo A, Ardanaz E, Rodríguez-Barranco M, Boeing H, Kaaks R, Khaw KT, Larrañaga N, Navarro C, Olsen A, Overvad K, Perez-Cornago A, Rohrmann S, Sánchez MJ, Tjønneland A, Tsilidis KK, Johansson M, Riboli E, Key TJ, Travis RC. Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Clin Oncol 2017; 35:1297-1303. [PMID: 28375714 PMCID: PMC5455458 DOI: 10.1200/jco.2016.70.0062] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Purpose Vasectomy is a commonly used form of male sterilization, and some studies have suggested that it may be associated with an increased risk of prostate cancer, including more aggressive forms of the disease. We investigated the prospective association of vasectomy with prostate cancer in a large European cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate cancer. Patients and Methods A total of 84,753 men from the European Prospective Investigation into Cancer and Nutrition (EPIC), aged 35 to 79 years, provided information on vasectomy status (15% with vasectomy) at recruitment and were followed for incidence of prostate cancer and death. We estimated the association of vasectomy with prostate cancer risk overall, by tumor subtype, and for death due to prostate cancer, using multivariable-adjusted Cox proportional hazards models. Results During an average follow-up of 15.4 years, 4,377 men were diagnosed with prostate cancer, including 641 who had undergone a vasectomy. Vasectomy was not associated with prostate cancer risk (hazard ratio [HR], 1.05; 95% CI, 0.96 to 1.15), and no evidence for heterogeneity in the association was observed by stage of disease or years since vasectomy. There was some evidence of heterogeneity by tumor grade ( P = .02), with an increased risk for low-intermediate grade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.07). Vasectomy was not associated with death due to prostate cancer (HR, 0.88; 95% CI, 0.68 to 1.12). Conclusion These findings from a large European prospective study show no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death due to prostate cancer in men who have undergone a vasectomy compared with men who have not.
Collapse
Affiliation(s)
- Karl Smith
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Byrne
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Jose Maria Castaño
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Maria Dolores Chirlaque
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Hans Lilja
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Antonio Agudo
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Eva Ardanaz
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Miguel Rodríguez-Barranco
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Heiner Boeing
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Rudolf Kaaks
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Kay-Tee Khaw
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Nerea Larrañaga
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Carmen Navarro
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Anja Olsen
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Kim Overvad
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Aurora Perez-Cornago
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Sabine Rohrmann
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Maria José Sánchez
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Anne Tjønneland
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Konstantinos K. Tsilidis
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Elio Riboli
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Timothy J. Key
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| | - Ruth C. Travis
- Karl Smith Byrne, Hans Lilja, Aurora Perez-Cornago, Timothy J. Key, and Ruth C. Travis, University of Oxford, Oxford; Kay-Tee Khaw, School of Clinical Medicine, University of Cambridge, Cambridge, Konstantinos K. Tsilidis and Elio Riboli, Imperial College London, London, United Kingdom; Jose Maria Castaño, Maria Dolores Chirlaque, and Carmen Navarro, Murcia Regional Health Council; Maria Dolores Chirlaque, IMIB-Arrixaca, Murcia; Jose Maria Castaño, Maria Dolores Chirlaque, Eva Ardanaz, Miguel Rodríguez-Barranco, Nerea Larrañaga, Carmen Navarro, and Maria José Sánchez, Center for Biomedical Research Network for Epidemiology and Public Health, Madrid; Antonio Agudo, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; Eva Ardanaz, Navarra Institute for Health Research, Pamplona; Miguel Rodríguez-Barranco and Maria José Sánchez, Universidad de Granada, Granada; Nerea Larrañaga, Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; Hans Lilja, Memorial Sloan Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; Heiner Boeing, German Institute of Human Nutrition, Potsdam-Rehbrücke; Rudolf Kaaks, German Cancer Research Center, Heidelberg, Germany; Anja Olsen and Anne Tjønneland, Danish Cancer Society Research Center, Copenhagen; Kim Overvad, Aarhus University, Aarhus, Denmark; Sabine Rohrmann, University of Zurich, Zurich, Switzerland; Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ionnina, Greece, and Mattias Johansson, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
39
|
Colagross-Schouten A, Lemoy MJ, Keesler RI, Lissner E, VandeVoort CA. The contraceptive efficacy of intravas injection of Vasalgel™ for adult male rhesus monkeys. Basic Clin Androl 2017; 27:4. [PMID: 28191316 PMCID: PMC5294830 DOI: 10.1186/s12610-017-0048-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 01/06/2017] [Indexed: 12/03/2022] Open
Abstract
Background Options for male contraception are limited. The purpose of this study was to use a nonhuman primate model to evaluate Vasalgel™, a high molecular weight polymer being developed as a contraceptive device for men. Methods Sixteen adult male rhesus monkeys received intravas injections of Vasalgel, consisting of 25% styrene maleic acid in dimethyl sulfoxide. After a one-week recovery, males were returned to outdoor group housing, which included at least 3 and up to 9 intact, breeding females with a successful reproductive history. Results Treated males have had no conceptions since Vasalgel injections. All males were housed with intact females for at least one breeding season and seven have been almost continually housed with females for 2 years. Complications were minor and included one incident of incorrect placement of Vasalgel into the vas deferens and the development of a sperm granuloma in one animal. Three unilateral vasectomies were performed, one was necessary for incorrect placement of Vasalgel, the other two were elective. Conclusions Intravas injection of Vasalgel in sexually mature adult male rhesus monkeys was effective in preventing conception in a free-living, group environment. Complications were few and similar to those associated with traditional vasectomy.
Collapse
Affiliation(s)
- Angela Colagross-Schouten
- California National Primate Research, University of California, One Shields Ave, Davis, CA 95616 USA
| | - Marie-Josee Lemoy
- California National Primate Research, University of California, One Shields Ave, Davis, CA 95616 USA
| | - Rebekah I Keesler
- California National Primate Research, University of California, One Shields Ave, Davis, CA 95616 USA
| | - Elaine Lissner
- Parsemus Foundation, PO Box 2246, Berkeley, CA 94702 USA
| | - Catherine A VandeVoort
- California National Primate Research, University of California, One Shields Ave, Davis, CA 95616 USA.,Department of Obstetrics and Gynecology, University of California, Davis, CA 95616 USA
| |
Collapse
|
40
|
Abstract
<p>Vasectomy is a safe and effective method of birth control. Although it is a simple elective procedure, vasectomy is associated with potential minor and major complications. The early failure rate of vasectomy (presence of motile sperm in the ejaculate at 3‒6 months post-vasectomy) is in the range of 0.3‒9% and the late failure rate is in the range of 0.04–0.08%. The no-scalpel vasectomy technique is associated with a lower risk of early postoperative complications and the use of cautery or fascial interposition will reduce the risk of contraceptive failure. As such, detailed preoperative counselling and careful assessment of the post-vasectomy ejaculate (for presence of sperm) is imperative. Failure to provide and document adequate information and counselling to patients may lead to litigation.</p><p>The focus of this guideline is the management of men presenting for vasectomy. Specifically, the topics covered include: preoperative counselling, vasectomy efficacy and complications, technical aspects of vasectomy, post-vasectomy semen testing, and interpretation-communication of post-vasectomy semen results. By performing an extensive literature review, we have generated an evidence-based consensus on the management of these men. The objective of this guideline is to help standardize the treatment of men presenting for vasectomy.</p>
Collapse
Affiliation(s)
- Armand Zini
- Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada
| | - John Grantmyre
- Department of Urology, Dalhousie University, Halifax, NS, Canada
| | - Peter Chan
- Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada
| |
Collapse
|
41
|
Lowe G. Optimizing outcomes in vasectomy: how to ensure sterility and prevent complications. Transl Androl Urol 2016; 5:176-80. [PMID: 27141443 PMCID: PMC4837312 DOI: 10.21037/tau.2016.03.04] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Vasectomy provides a long-term effective sterilization for men and is performed on nearly 500,000 men annually in the United States. Improvements in technique have led to a decreased failure rate and fewer complications, although significant variations in technique exist. Use of cautery occlusion with or without fascial interposition appears to have the least failures. A no-scalpel approach lowers risk of hematoma formation, infection and bleeding post-operatively. A patient can be considered sterile when azoospermia is achieved or the semen analysis shows less than 100,000 non-motile sperm per milliliter. Incorporating these principles may allow the physician to optimize outcomes in vasectomy.
Collapse
|
42
|
Tan WP, Levine LA. An overview of the management of post-vasectomy pain syndrome. Asian J Androl 2016; 18:332-7. [PMID: 26952956 PMCID: PMC4854072 DOI: 10.4103/1008-682x.175090] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 12/17/2015] [Accepted: 12/18/2015] [Indexed: 11/13/2022] Open
Abstract
Post-vasectomy pain syndrome remains one of the more challenging urological problems to manage. This can be a frustrating process for both the patient and clinician as there is no well-recognized diagnostic regimen or reliable effective treatment. Many of these patients will end up seeing physicians across many disciplines, further frustrating them. The etiology of post-vasectomy pain syndrome is not clearly delineated. Postulations include damage to the scrotal and spermatic cord nerve structures via inflammatory effects of the immune system, back pressure effects in the obstructed vas and epididymis, vascular stasis, nerve impingement, or perineural fibrosis. Post-vasectomy pain syndrome is defined as at least 3 months of chronic or intermittent scrotal content pain. This article reviews the current understanding of post-vasectomy pain syndrome, theories behind its pathophysiology, evaluation pathways, and treatment options.
Collapse
Affiliation(s)
- Wei Phin Tan
- Department of Urology, Rush University Medical Center, Chicago, Illinois, USA
| | - Laurence A Levine
- Department of Urology, Rush University Medical Center, Chicago, Illinois, USA
| |
Collapse
|
43
|
CURRENT STATE OF THE MALE INFERTILITY PROBLEM:THE REVIEW OF EUROPEAN ASSOCIATION OF UROLOGY CLINICAL GUIDELINES. КЛИНИЧЕСКАЯ ПРАКТИКА 2016. [DOI: 10.17816/clinpract7139-50] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The article highlights the problem of male infertility on the basis of review of the latest guidelines of European Association of urology
Collapse
|
44
|
Canadian Contraception Consensus Chapter 6 Permanent Contraception. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2015. [DOI: 10.1016/s1701-2163(16)39377-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Alpcan S, Başar H, Aydos TR, Kul O, Kısa Ü, Başar MM. Apoptosis in testicular tissue of rats after vasectomy: evaluation of eNOS, iNOS immunoreactivities and the effects of ozone therapy. Turk J Urol 2015; 40:199-206. [PMID: 26328178 DOI: 10.5152/tud.2014.76892] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Accepted: 10/27/2014] [Indexed: 11/22/2022]
Abstract
OBJECTIVE We aimed to investigate the changes in endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) expression and apoptotic index in rat testicular tissue, as well as serum and seminal plasma sex hormone levels after vasectomy, and the effect of ozone therapy (OT). MATERIAL AND METHODS Adult male Wistar rats were used (n=6 per group). Control (G1), sham for 4 weeks (G2) or 6 weeks (G3), orchiectomy at the 4(th) (G4) or 6(th) (G5) week after left vasectomy, orchiectomy at the 4(th) (G6) or 6(th) (G7) week after bilateral vasectomy, orchiectomy after 6 weeks OT following left (G8) or bilateral (G9) vasectomy, orchiectomy after 6 weeks OT (G10). RESULTS In the left testes, while there were increases in eNOS and iNOS immunoreactivity and apoptotic indexes in G4 and G5, no changes were observed in contralateral testis. These values increased in G6 and G7, while OT inhibited these parameters in the left testis of G8 and both testes of G9. Sex hormone levels did not show any changes after vasectomy and ozone therapy. CONCLUSION While OT was found to be protective against some parameters mentioned above under stress conditions, it seemed to cause some harmful effects when used in healthy conditions.
Collapse
Affiliation(s)
- Serhan Alpcan
- Department of Urology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
| | - Halil Başar
- Department of Urology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
| | - Tolga Reşat Aydos
- Department of Pharmacology, Başkent University Faculty of Medicine, Ankara, Turkey
| | - Oğuz Kul
- Department of Pathology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
| | - Üçler Kısa
- Department of Biochemistry, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
| | - Murad Mehmet Başar
- Department of Urology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
| |
Collapse
|
46
|
Guo DP, Lamberts RW, Eisenberg ML. Relationship between Vasectomy and Sexual Frequency. J Sex Med 2015; 12:1905-10. [DOI: 10.1111/jsm.12962] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
|
48
|
Liu LH, Kang R, He J, Zhao SK, Li FT, Wan SP, Zhao ZG. Vasectomy and risk of prostate cancer: a systematic review and meta-analysis of cohort studies. Andrology 2015; 3:643-9. [PMID: 26041315 DOI: 10.1111/andr.12040] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 03/13/2015] [Accepted: 03/27/2015] [Indexed: 01/11/2023]
Affiliation(s)
- L. H. Liu
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - R. Kang
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - J. He
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - S. K. Zhao
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - F. T. Li
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - S. P. Wan
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Z. G. Zhao
- Department of Urology & Andrology; Minimally Invasive Surgery Center; Guangdong Key Laboratory of Urology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| |
Collapse
|
49
|
Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol 2015; 32:3033-8. [PMID: 25002716 DOI: 10.1200/jco.2013.54.8446] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Conflicting reports remain regarding the association between vasectomy, a common form of male contraception in the United States, and prostate cancer risk. We examined prospectively this association with extended follow-up and an emphasis on advanced and lethal disease. PATIENTS AND METHODS Among 49,405 U.S. men in the Health Professionals Follow-Up Study, age 40 to 75 years at baseline in 1986, 6,023 patients with prostate cancer were diagnosed during the follow-up to 2010, including 811 lethal cases. In total, 12,321 men (25%) had vasectomies. We used Cox proportional hazards models to estimate the relative risk (RR) and 95% CIs of total, advanced, high-grade, and lethal disease, with adjustment for a variety of possible confounders. RESULTS Vasectomy was associated with a small increased risk of prostate cancer overall (RR, 1.10; 95% CI, 1.04 to 1.17). Risk was elevated for high-grade (Gleason score 8 to 10; RR, 1.22; 95% CI, 1.03 to 1.45) and lethal disease (death or distant metastasis; RR, 1.19; 95% CI, 1.00 to 1.43). Among a subcohort of men receiving regular prostate-specific antigen screening, the association with lethal cancer was stronger (RR, 1.56; 95% CI, 1.03 to 2.36). Vasectomy was not associated with the risk of low-grade or localized disease. Additional analyses suggested that the associations were not driven by differences in sex hormone levels, sexually transmitted infections, or cancer treatment. CONCLUSION Our data support the hypothesis that vasectomy is associated with a modest increased incidence of lethal prostate cancer. The results do not appear to be due to detection bias, and confounding by infections or cancer treatment is unlikely.
Collapse
|
50
|
|